et190l1 artemis™ t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2017 (NCT03415399)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03379493 | Phase 1 | Apr 4, 2018 | Aeon Therapeutics (Shanghai) Co., Ltd., Duke University |
| NCT03895944 | Early Phase 1 (Phase 1) | Dec 6, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd., Jiao Tong University |
| NCT03415399 | Phase 1 | Sep 9, 2017 | Aeon Therapeutics (Shanghai) Co., Ltd., Peking University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aeon Therapeutics (Shanghai) Co., Ltd. | For profit | 3 | 2 | 1 | 2017 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1